Nuclear factor kappaB inducing factor

A nucleic acid encoding NFIF-7a polypeptide comprising an amino acid sequence as shown in FIG. 2 (SEQ ID NO:

• 2).

An isolated and purified NFIF-14b polypeptide which induces NFκB and comprising an amino acid sequence as shown in FIG. 1 (SEQ ID NO:

• 1).

An isolated and purified NFIF-7a polypeptide which induces NFκB and comprising an amino acid sequence as shown in FIG. 2 (SEQ ID NO:

• 2).

A method of increasing expression of NFκB in a patient comprising introducing into the body of said patient a composition that induces NFκB.

A composition for lowering the expression of the NFIF gene in a patient comprising an antisense nucleic acid.

A composition for lowering the activity of an NFIF polypeptide in a patient comprising a neutralizing antibody that binds to an NFIF polypeptide and lowers its activity.

A composition for lowering the expression of NFIF in a patient comprising a ribozyme that cuts RNA encoding an NFIF polypeptide.

A method of inhibiting expression of NFκB-dependent genes comprising administration to a patient of a composition that inhibits the activity of NFIF-14b.

A method of inhibiting expression of NFκB-dependent genes comprising administration to a patient of a composition that inhibits the activity of NFIF-7a.

A method of inhibiting inflammation comprising administration of a composition that inhibits the activity of NFIF-14b.

A method of inhibiting inflammation comprising administration of a composition that inhibits the activity of NFIF-7a.

Use of an isolated NFIF polypeptide comprising an amino acid sequence of FIG. 1 (SEQ ID NO:

• 1) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

Use of a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of FIG. 1 (SEQ ID NO:

• 1) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

Use of a recombinant vector comprising a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of FIG. 1 (SEQ ID NO:

• 1) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

Use of a defective recombinant viral vector comprising a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of FIG. 1 (SEQ ID NO:

• 1) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

Use of an isolated NFIF polypeptide comprising an amino acid sequence of FIG. 2 (SEQ ID NO:

• 2) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

Use of a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of FIG. 2 (SEQ ID NO:

• 2) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

Use of a recombinant vector comprising a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of FIG. 2 (SEQ ID NO:

• 2) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

Use of a defective recombinant viral vector comprising a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of FIG. 2 (SEQ ID NO:

• 2) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.